Victrex plc (VCT)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 898.00 |
|---|---|
| 52-week range | 515.00 – 1,024.00 |
| Return, 1 month / 3 months | −9.3% / +23.4% |
| Return, 1 year / 3 years | +47.6% / −18.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 44 |
| Volatility (1 year) | 36.7% |
| Worst drawdown (1 year) | -24.0% |
| Average daily value traded | 256.12M GBX |
| Dividend yield | 6.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Victrex plc is a British materials company that makes high-performance polymers, most notably polyetheretherketone, which it markets under its own brand name. These engineering plastics are supplied as granules and finished shapes to customers in medical technology, aerospace, automotive, electronics and general industrial markets, where parts must withstand heat, wear and chemicals. The company is based in Lancashire, England, and also produces related products such as films and composite materials for specialised uses.
On this site Victrex plc appears as a stock on the London Exchange (UK), code VCT, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Victrex plc (VCT) trades on the London Exchange in UK. It last closed at GBX 898.00 on 22 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 112 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 47.6% and over the last three months it rose 23.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 27.0% | ||
| From 52-week high | -11.1% | ||
| Momentum | 92 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.4% | ||
| 6-month return | 43.3% | ||
| 12-month return, skipping the last month | 62.7% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.0% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 256.12M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 64 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 6.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −4.0% |
|---|---|
| 1 month | −9.3% |
| 3 months | +23.4% |
| 6 months | +43.3% |
| 1 year | +47.6% |
| 3 years | −18.7% |
| 5 years | −48.9% |
Signals
| 50-day / 200-day average | 900.12 / 706.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 31.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 May 2026 | GBP 0.1342 |
| 29 Jan 2026 | GBP 0.4614 |
| 29 May 2025 | GBP 0.1342 |
| 23 Jan 2025 | GBP 0.4614 |
| 30 May 2024 | GBP 0.1342 |
| 25 Jan 2024 | GBP 0.4614 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.